Application of the MAPK pathway inhibitor PD98059 in bleomycin-induced IPF mice attenuates ERK phosphorylation and inflammatory factor phosphorylation of JNK protein, alleviating lung inflammatory reactions and interstitial fibrosis, thereby providing clear protective effects against bleomycin-induced lung injury [26]. Here, MAPK1 is linked to idiopathic pulmonary fibrosis.